World’s First Patient Dose Administered in Combination of Asieris’ APL-1202 and BeiGene’s Tislelizumab as Neoadjuvant Therapy for MIBC Patients
The CDE Approved IND Application to Investigate Combination of Asieris’ APL-1202 and BeiGene’s Tislelizumab as Neoadjuvant Therapy for MIBC Patients
Asieris Appoints Dr. Alice Chen as Vice President, Discovery Biology and Head of Translational Research
Asieris Announces First Patient Treated in Europe in APRICITY, the Multinational Phase III Clinical Trial of APL-1702, Cevira®
The U.S. FDA Approved IND Application to Investigate Combination of Asieris’ APL-1202 and BeiGene’s Tislelizumab as Neoadjuvant Therapy for MIBC Patients
Asieris and Sinopharm Enter into Strategic Partnership to Accelerate Commercialization of Asieris Products
